Announcement • Mar 25
Insilico Co. Ltd. completed the acquisition of 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu. Insilico Co. Ltd. entered into a stock transfer agreement to acquire 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu for KRW 16.1 billion on March 9, 2026. A cash consideration of KRW 16.13 billion will be paid by Insilico Co. Ltd. As part of consideration, KRW 16.13 billion is paid towards common equity of Daesung Microbiological Labs. Co., Ltd.
The expected completion of the transaction is March 31, 2026.
Insilico Co. Ltd. completed the acquisition of 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu on March 24, 2026. The transaction was funded through equity funds of KRW 2.63 billion and borrowings of KRW 13.5 billion. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩8,120, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total loss to shareholders of 17% over the past three years. Announcement • Feb 12
Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 24, 2026 Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 103, deogyeong-daero, gyeonggi-do, uiwang South Korea Upcoming Dividend • Dec 22
Upcoming dividend of ₩75.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 27 April 2026. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%). Reported Earnings • Nov 12
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: ₩7.18b (up 24% from 3Q 2024). Net income: ₩752.6m (up ₩2.08b from 3Q 2024). Profit margin: 11% (up from net loss in 3Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Declared Dividend • Nov 08
Dividend of ₩75.00 announced Dividend of ₩75.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 27th April 2026 Dividend yield will be 1.1%, which is higher than the industry average of 0.5%. Sustainability & Growth The dividend has not increased over the past 4 years but payments have been stable during that time. Announcement • Nov 07
Daesung Microbiological Labs. Co., Ltd. announces Annual dividend, payable on April 27, 2026 Daesung Microbiological Labs. Co., Ltd. announced Annual dividend of KRW 75.0000 per share payable on April 27, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Announcement • Feb 26
Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2025 Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 103, deogyeong-daero, gyeonggi-do, uiwang South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩75.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 23 April 2025. The company last paid an ordinary dividend in April 2022. The average dividend yield among industry peers is 0.5%. New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩36.2b market cap, or US$25.2m). Declared Dividend • Nov 14
Dividend of ₩75.00 announced Shareholders will receive a dividend of ₩75.00. Ex-date: 27th December 2024 Payment date: 23rd April 2025 Dividend yield will be 0.8%, which is higher than the industry average of 0.5%. Upcoming Dividend • Dec 20
Upcoming dividend of ₩75.00 per share at 0.7% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.7%). New Risk • Oct 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Profit margins are more than 30% lower than last year (1.8% net profit margin). Market cap is less than US$100m (₩55.2b market cap, or US$40.8m). Reported Earnings • May 18
First quarter 2023 earnings released: EPS: ₩40.00 (vs ₩454 in 1Q 2022) First quarter 2023 results: EPS: ₩40.00 (down from ₩454 in 1Q 2022). Revenue: ₩5.73b (down 9.9% from 1Q 2022). Net income: ₩152.2m (down 91% from 1Q 2022). Profit margin: 2.7% (down from 27% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • May 11
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩12,790, the stock trades at a trailing P/E ratio of 28.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 7.6% over the past three years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩75.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 19 April 2023. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩10,000, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 21x in the Biotechs industry in South Korea. Total loss to shareholders of 44% over the past three years. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩11,850, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 36% over the past three years. Reported Earnings • May 18
First quarter 2022 earnings released: EPS: ₩454 (vs ₩6.00 in 1Q 2021) First quarter 2022 results: EPS: ₩454 (up from ₩6.00 in 1Q 2021). Revenue: ₩6.36b (up 14% from 1Q 2021). Net income: ₩1.73b (up ₩1.70b from 1Q 2021). Profit margin: 27% (up from 0.5% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Dec 22
Inaugural dividend of ₩85.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit and is not cash flow positive. This is the first dividend for Daesung Microbiological Labs since going public. The average dividend yield among industry peers is 0.8%. Reported Earnings • May 19
First quarter 2021 earnings released: EPS ₩6.00 (vs ₩204 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩5.60b (down 18% from 1Q 2020). Net income: ₩25.7m (down 97% from 1Q 2020). Profit margin: 0.5% (down from 12% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Feb 25
Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2021 Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2021, at 09:00 Korea Standard Time. Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment improved over the past week After last week's 19% share price gain to ₩21,600, the stock is trading at a trailing P/E ratio of 33.7x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 62x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 102%. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment improved over the past week After last week's 30% share price gain to ₩21,700, the stock is trading at a trailing P/E ratio of 33.8x, up from the previous P/E ratio of 26x. This compares to an average P/E of 57x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 111%. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment improved over the past week After last week's 26% share price gain to ₩20,600, the stock is trading at a trailing P/E ratio of 32.1x, up from the previous P/E ratio of 25.5x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 102%. Is New 90 Day High Low • Jan 11
New 90-day high: ₩20,600 The company is up 24% from its price of ₩16,600 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 20% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩85.00 Per Share Will be paid on the 17th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in March 2010. The average dividend yield among industry peers is 0.3%.